Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS626 vs Remicade in chronic moderate-to-severe plaque psoriasis
CTR20180351Phase 3Completed
- Sponsor
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of infliximab in plaque psoriasis, sponsored by Zhejiang Hisun Pharmaceutical Co., Ltd.. Started Apr 2018; status: completed.
02
Drugs
infliximab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20180351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180351.